EP0303465A2 — Phenethanolamine derivatives
Assigned to Glaxo Group Ltd · Expires 1989-02-15 · 37y expired
What this patent protects
The invention provides compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein Z represents the group (wherein Q 1 represents a straight or branched C 1-3 alkylene group), (where Q 2 represents a group R S CO-, R 5 …
USPTO Abstract
The invention provides compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein Z represents the group (wherein Q 1 represents a straight or branched C 1-3 alkylene group), (where Q 2 represents a group R S CO-, R 5 NHCO-, R 5 R 6 NS0 2 -or R 7 S0 2 -, where R 5 and R 6 each represent a hydrogen atom or a C 1 - 3 alkyl group, and R 7 represents a C 1-3 alkyl group), or X represents a bond, or a C 1 - 7 alkylene, C 2 - 7 alkenylene or C 2 - 7 alkynylene chain, and Y represents a bond, or a C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene chain with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10; R represents a hydrogen atom or a C 1-3 alkyl group; R 1 and R 2 each represent a hydrogen atom or a C 1-3 alkyl group: with the proviso that the sum total of carbon atoms in R 1 and R 2 is not more than 4; and Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is (are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from C 1-4 alkyl, C 1 - 4 alkoxy, hydroxy, halogen, -NR 3 R 4 and -COR 8 ; where R 3 and R 4 each represent a hydrogen atom or a Ci- 4 alkyl group or -NR 3 R 4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -0- or -S- or a group -NH-or-N(CH 3 )-; and R 8 represents hydroxy, C 1-4 alkoxy or -NR 3 R 4 . The compounds have a stimulant action of β2- adrenorecep- tors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.